Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 5.8K citations · Full text

Medicine, Oncology, Pharmacology +14

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Cora N. Sternberg, Ian D. Davis, Jozef Mardiak et al. · Journal of Clinical Oncology · 2010 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Bernard Escudier, Camillo Porta, Manuela Schmidinger et al. · Annals of Oncology · 2014 · 2.3K citations · Full text

Medicine, Nephrology, Oncology +14

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Bernard Escudier, P. Koralewski, Alain Ravaud et al. · The Lancet · 2007 · 2.2K citations

Medicine, Oncology, Pharmacotherapy +16

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Scott M. Wilhelm, Jacques Dumas, Lila Adnane et al. · International Journal of Cancer · 2010 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17